3-isopropoxy-5-(2-oxopyrrolidin-1-yl)benzoic acid | 537657-94-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-isopropoxy-5-(2-oxopyrrolidin-1-yl)benzoic acid
• 英文别名: 3-(2-oxopyrrolidin-1-yl)-5-propan-2-yloxybenzoic acid
• CAS: 537657-94-6
• 化学式: C₁₄H₁₇NO₄
• 分子量: 263.293
• InChiKey: FCVQQNKDUCCGJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-isopropoxy-5-(2-oxopyrrolidin-1-yl)benzoic acid 、 (2S)-2-[[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]amino]-N-cyclohexylpropanamide 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[(2S,3R)-4-[[(2S)-1-(cyclohexylamino)-1-oxopropan-2-yl]amino]-3-hydroxy-1-phenylbutan-2-yl]-3-(2-oxopyrrolidin-1-yl)-5-propan-2-yloxybenzamide
  参考文献：
  名称：

  BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs)

  摘要：

  Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. Herein, is described the lead generation effort which resulted, with the support of X-ray crystallography, in the discovery of potent inhibitors based on a hydroxy ethylamine (HEA) transition-state mimetic. These inhibitors were capable of lowering amyloid production in a cell-based assay.

  DOI：

  10.1016/j.bmcl.2007.12.017
• 作为产物：
  描述：

  3-hydroxy-5-(2-oxopyrrolidin-1-yl)benzoic acid methyl ester 、 alkaline earth salt of/the/ methylsulfuric acid 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 3-isopropoxy-5-(2-oxopyrrolidin-1-yl)benzoic acid
  参考文献：
  名称：

  BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs)

  摘要：

  Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. Herein, is described the lead generation effort which resulted, with the support of X-ray crystallography, in the discovery of potent inhibitors based on a hydroxy ethylamine (HEA) transition-state mimetic. These inhibitors were capable of lowering amyloid production in a cell-based assay.

  DOI：

  10.1016/j.bmcl.2007.12.017

文献信息

• Benzamide derivatives, processes for their preparation, and their pharmaceutical use
  申请人：Faller Andrew

  公开号：US20050085520A1

  公开（公告）日：2005-04-21

  The present invention relates to novel hydroxyethylene compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及一种新型的羟基乙烯化合物，具有Asp2（β-分泌酶，BACE1或Memapsin）抑制活性，其制备过程，包含它们的组合物以及它们在治疗β-淀粉样蛋白水平或β-淀粉样蛋白沉积物升高的疾病，特别是阿尔茨海默病中的用途。
• Hydroxyethylamine derivatives for the treatment of alzheimer's disease
  申请人：Demont H Emmanuel

  公开号：US20060025459A1

  公开（公告）日：2006-02-02

  The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及具有Asp2（β-秘鲁酶、BACE1或Memapsin）抑制活性的新型羟乙基胺化合物，其制备方法，包含它们的组合物以及它们在治疗由高β-淀粉样蛋白水平或β-淀粉样蛋白沉积物所特征的疾病，特别是阿尔茨海默病中的应用。
• BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1448520A1

  公开（公告）日：2004-08-25
• HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：GLAXO GROUP LIMITED

  公开号：EP1567488B1

  公开（公告）日：2007-02-21
• US6992103B2
  申请人：——

  公开号：US6992103B2

  公开（公告）日：2006-01-31